



PATENT

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Joseph Pontillo et al.  
 Application No. : 10/705,762  
 Filed : November 10, 2003  
 For : GONADOTROPIN-RELEASING HORMONE  
 RECEPTOR ANTAGONISTS AND METHODS  
 RELATING THERETO  
 Art Unit : 1624  
 Docket No. : 690068.552C1  
 Date : December 10, 2004

Mail Stop Missing Parts  
 Commissioner for Patents  
 P.O. Box 1450  
 Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents:

In accordance with 37 C.F.R. §§ 1.56 and 1.97 through 1.98, applicants wish to make known to the Patent and Trademark Office the references set forth on the attached Form PTO-1449. This application is a continuation and relies, under 35 U.S.C. § 120, on the earlier filing date of prior Application No. 10/211,992, filed August 2, 2002, now U.S. Patent 6,673,796. The references listed on the attached Form PTO-1449 were submitted to and/or cited by the Patent and Trademark Office in this prior application and, therefore, are not required to be provided in this application. If the Examiner wishes, copies will be provided upon request. As to any reference supplied, applicants do not admit that it is "prior art" under 35 U.S.C. §§ 102 or 103, and specifically reserve the right to traverse or antedate any such reference, as by a showing under 37 C.F.R. § 1.131 or other method. Although the aforesaid references are made known to the Patent and Trademark Office in compliance with applicants' duty to disclose all information they are aware of which is believed relevant to the examination of the above-identified application, applicants believe that their invention is patentable.

Please acknowledge receipt of this Information Disclosure Statement and kindly make the cited references of record in the above-identified application.

Applicants believe this Information Disclosure Statement has been timely filed, however, the Director is authorized to charge any fee due by way of this Information Disclosure Statement to our Deposit Account No. 19-1090.

Respectfully submitted,  
Seed Intellectual Property Law Group PLLC

  
\_\_\_\_\_  
Karl R. Hermanns  
Registration No. 33,507

Enclosures:

Form PTO-1449

701 Fifth Avenue, Suite 6300  
Seattle, Washington 98104-7092  
Phone: (206) 622-4900  
Fax: (206) 682-6031

464480



EXPRESS MAIL NO. EV449565202US

Sheet 1 of 2

FORM PTO-1449 (REV.7-80)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE			ATTY. DOCKET NO. <b>690068.552C1</b>	APPLICATION NO. <b>10/705,762</b>	
<b>INFORMATION DISCLOSURE STATEMENT</b> <i>(Use several sheets if necessary)</i>			APPLICANTS <b>Joseph Pontillo et al.</b>			
			FILING DATE <b>November 10, 2003</b>	GROUP ART UNIT <b>1624</b>		

**U.S. PATENT DOCUMENTS**

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	AA	5,780,437	07/14/98	Goulet et al.	514	19	
	AB	5,849,764	12/15/98	Goulet et al.	514	337	

**FOREIGN PATENT DOCUMENTS**

		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION	
					YES	NO
	AC	48-28026	08/14/71	JP		
	AD	748 800	12/18/96	EP		
	AE	WO 96/38438	12/05/96	WIPO		
	AF	WO 97/14682	04/24/97	WIPO		
	AG	WO 97/14697	04/24/97	WIPO		
	AH	WO 97/21435	06/19/97	WIPO		
	AI	WO 97/21703	06/19/97	WIPO		
	AJ	WO 97/21704	06/19/97	WIPO		
	AK	WO 97/21707	06/19/97	WIPO		
	AL	WO 97/44037	11/27/97	WIPO		
	AM	WO 97/44041	11/27/97	WIPO		
	AN	WO 97/44321	11/27/97	WIPO		
	AO	WO 97/44339	11/27/97	WIPO		
	AP	WO 98/55116	12/10/98	WIPO		
	AQ	WO 98/55119	12/10/98	WIPO		

**OTHER PRIOR ART** *(Including Author, Title, Date, Pertinent Pages, Etc.)*

AR	Abstract of JP48-28,026, Chemical Abstracts Volume 75 Number 21, 1971.
----	--

EXAMINER	DATE CONSIDERED
----------	-----------------

\* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).

FORM PTO-1449 (REV.7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. 690068.552C1	APPLICATION NO. 10/705,762
<b>INFORMATION DISCLOSURE STATEMENT</b> <i>(Use several sheets if necessary)</i>		APPLICANTS Joseph Pontillo et al.			
		FILING DATE November 10, 2003	GROUP ART UNIT 1624		

**U.S. PATENT DOCUMENTS**

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	BA						
	BB						
	BC						

**FOREIGN PATENT DOCUMENTS**

		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION	
					YES	NO
	BD	WO 98/55470	12/10/98	WIPO		
	BE	WO 98/55479	12/10/98	WIPO		
	BF	WO 99/09033	02/25/99	WIPO		
	BG	WO 99/33831	07/08/99	WIPO		
	BH	WO 00/56739	09/28/00	WIPO		
	BI	WO 00/69859	11/23/00	WIPO		
	BJ	WO 01/29044	04/26/01	WIPO		

**OTHER PRIOR ART** *(Including Author, Title, Date, Pertinent Pages, Etc.)*

BK		Al-Damluji et al., “ $\alpha_{1B}$ Adrenergic Receptors in Gonadotrophin-Releasing Hormone Neurones: Relation to Transport-P,” <i>British Journal of Pharmacology</i> 132:336-344, 2001.
BL		Burch, “Nitrofuryl Heterocycles. X. <sup>1</sup> Analogs of 6-(5-Nitro-2-furyl)-as-Triazine-3,5(2H,4H)-dione,” <i>Journal of Medicinal Chemistry</i> 13:288-291, 1970.
BM		Cho et al., “Discovery of a Novel, Potent, and Orally Active Nonpeptide Antagonist of the Human Luteinizing Hormone-Releasing Hormone (LHRH) Receptor,” <i>J Med Chem.</i> 41(22):4190-4195, October 22, 1998.
BN		Huirne, J. et al., “Gonadotropin-Releasing-Hormone-Receptor Antagonists,” <i>Lancet</i> 358(9295):1793-1803, November 2001.
BO		Stanislaus et al., “Regulation of Gq/11 $\alpha$ by the Gonadotropin-Releasing Hormone Receptor,” <i>Molecular Endocrinology</i> 11:738-746, 1997.

EXAMINER	DATE CONSIDERED
----------	-----------------

\* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).